- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05014594
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
The development of ascites is a landmark event in the natural history of cirrhosis and signifies a grim prognosis. Portal hypertension and splanchnic arterial vasodilatation are the major contributors in the development of ascites. Vasodilatation with the consequential decrease in effective circulating volume leads to the activation of sympathetic nervous system and renin angiotensin aldosterone system (RAAS), leading to antinatriuretic effects and retention of sodium and water. This results in the formation of ascites. Management of ascites primarily consists of salt restrictrion and diuretics. Liver transplant is the ultimate panacea.
Dapaglifozin, a Sodium glucose linked transporter-2(SGLT-2) inhibitor, is a part of the routine armamentarium for treatment of patients with Diabetes Mellitus type-2. Its safety is well established in non-diabetic patients too where it has been shown to improve cardiovascular outcomes. The risk of hypoglycemia is negligible as its action is independent of insulin. By virtue of its natriuretic effect, it has been shown to reduce hospitalisations in patients with heart failure irrespective of the presence of diabetes. We hypothesise that a similar natriuretic effect may help in suppressing the renin-angiotensin axis with improved mobilization of ascites in patients with cirrhosis. Pharmacokinetic data on the use of Dapaglifozin suggest that there is no need for dose modification in cirrhosis. The AUC and Cmax for Dapaglifozin in Child Pugh C cirrhosis is 67% and 40%, respectively. In a recent small case series, SGLT-2 inhibitors including dapaglifozin led to improvement in fluid retention and serum sodium, without acute kidney injury or encephalopathy, in patients with cirrhosis. However, SGLT-2 inhibitors have not been evaluated in randomized controlled trials. In this pilot study, we plan to evaluate the efficacy and safety of dapaglifozin in cirrhotics patients with recurrent ascites.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Virendra Singh, MD,DM,FASGE
- Telefonnummer: 0172-275-6338
- E-mail: virendrasingh100@hotmail.com
Undersøgelse Kontakt Backup
- Navn: Rishav Aggarwal, MBBS
- Telefonnummer: 9914032190
- E-mail: rishavaggarwal90@gmail.com
Studiesteder
-
-
-
Chandigarh, Indien, 160012
- Rekruttering
- Dept of Hepatology, PGIMER
-
Kontakt:
- Virendra Singh, MD, DM
- Telefonnummer: +911722756338
- E-mail: virendrasingh100@hotmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18-70 years
- Cirrhosis as determined by clinical findings, hemogram and liver function tests, endoscopic findings and imaging
- Recurrent ascites: Recurrent ascites will be defined as tense ascites recurring at least thrice within the last 1-year despite optimal standard medical treatment including large volume paracentesis and diuretics
Exclusion Criteria:
- Presence of chronic kidney disease as defined by an estimated glomerular filtration rate of <60 ml/min for more than 3 months. The MDRD-6 equation will be used for estimating GFR.
- Portal vein thrombosis
- Hepatocellular carcinoma.
- Gastrointestinal bleed in the preceding 2-weeks
- Overt hepatic encephalopathy in the preceding 1-month
- Documented hypoglycemia in the preceding 1-month
- Serum sodium < 125 meq/l
- History of skeletal fracture in the preceding year or any past history of fragility fracture
- History of peripheral vascular disease
- Acute kidney injury as defined by the International Club of Ascites criteria
- Infection within 1-month preceding the study
- Anatomic urologic defects that predispose to urinary tract infection
- Mixed ascites (additional etiology of ascites apart from portal hypertension)
- Any severe extra hepatic condition including respiratory and cardiac failure
- Acute-on-chronic liver failure as per the APASL or CANONIC criteria
- Treatment with drug with known effects on systemic and renal hemodynamics within 7 days of inclusion excepting beta-blockers
- Patients opting for liver transplant or TIPS
- Refusal to give consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Group A (Dapaglifozin)
Group A will receive oral Dapaglifozin (10 mg/day) along with standard medical therapy for 6 months
|
Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
|
Placebo komparator: Group B (Placebo)
Group B will receive placebo of Dapaglifozin along with standard medical therapy for 6 months
|
Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care.
Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
control of ascites at 6-months
Tidsramme: 6 months
|
Control of ascites will be defined as follows-
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in eGFR measured by MDRD-6 at 3 months and 6 months
Tidsramme: 6 months
|
eGFR will be measured by MDRD-6 formula
|
6 months
|
Change in urine output at 2-weeks, 3-months and 6-months
Tidsramme: 6-months
|
Change in 24-hour urine output (ml) at 6-months
|
6-months
|
Change in serum sodium (mEq/l) at 2-weeks, 3-months and 6 months
Tidsramme: 6 months
|
Change in serum sodium (mEq/l)
|
6 months
|
Change in 24-hours urinary sodium (mEq) at 2 weeks, 3 months and 6 months
Tidsramme: 6 months
|
Change in 24-hours urinary sodium (mEq)
|
6 months
|
Change in HbA1c at 3 and 6 months
Tidsramme: 6 months
|
Change in HbA1c
|
6 months
|
Change in Child-Turcotte-Pugh (CTP) score at 3 months and 6 months
Tidsramme: 6 months
|
Change in CTP score.
The CTP score incorporates the variables of serum bilirubin, albumin, prothrombin time-INR, grade of ascites and hepatic encephalopathy.
The score ranges from 5-15 and a higher score portends a worse prognosis
|
6 months
|
Change in model for end stage liver disease (MELD) score at 3 months and 6 months
Tidsramme: 6 months
|
Change in MELD score.
The MELD score incorporates the variables of serum bilirubin, creatinine and Internation Normalised Ratio (INR).
Higher MELD score indicates worse prognosis
|
6 months
|
Incidence of spontaneous bacterial peritonitis (SBP), urinary tract infection (UTI) and other infections
Tidsramme: 6 months
|
The diagnosis of SBP will be based on neutrophil count in ascitic fluid of >250/mm3 as determined by microscopy and positive ascitic fluid culture or >250 /mm3 with negative culture called as culture negative neutrocytic ascites.Other infections will be diagnosed as per CDC criteria.
|
6 months
|
Incidence of overt hepatic encephalopathy over 6-months
Tidsramme: 6 months
|
Over hepatic encephalopathy (HE) will be defined as grade II or higher HE as per the West haven classification
|
6 months
|
Incidence of acute kidney injury over 6-months
Tidsramme: 6 months
|
Acute kidney injury will be defined as per the International Club of Ascites criteria
|
6 months
|
Incidence of Hyponatremia (serum sodium <130 meq/L), hypokalemia (Serum potassium < 3.5 meq/L), hyperkalemia (Serum potassium >6meq/L) over 6-months.
Tidsramme: 6 months
|
Hyponatremia: serum sodium <130 meq/L hypokalemia: serum potassium < 3.5 meq/L hyperkalemia: serum potassium >6meq/L)
|
6 months
|
Incidence of skeletal fractures over 6-months
Tidsramme: 6 months
|
Incidence of skeletal fractures over 6-months
|
6 months
|
Change in bone densitometry as assessed by DEXA at 6-months
Tidsramme: 6 months
|
Bone densitometry will be assessed by DEXA
|
6 months
|
Incidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic coma over 6-months
Tidsramme: 6 months
|
Incidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic coma over 6-months
|
6 months
|
Incidence of hepatocellular carcinoma over 6-months
Tidsramme: 6 months
|
Hepatocellular carcinoma will be diagnosed based on imaging findings and AFP
|
6 months
|
Changes in plasma renin activity and aldosterone levels at 6- months
Tidsramme: 6 months
|
Changes in plasma renin activity (ng/ml/hr) and aldosterone (ng/dL) levels at 6- months
|
6 months
|
Frequency and volume of LVP over 6-months.
Tidsramme: 6 months
|
Frequency and volume of ascitic fluid removed (in litres) over 6-months.
|
6 months
|
Survival at 6-months
Tidsramme: Survival at 6-months
|
Survival at 6-months after start of therapy
|
Survival at 6-months
|
Safety of dapaglifozin as assessed by adverse effects
Tidsramme: 6 months
|
Safety of dapaglifozin as assessed by adverse effects
|
6 months
|
Renal resistive index at 6 months
Tidsramme: 6 months
|
Renal resistive index will be measured using ultrasound doppler interrogation of intrarenal arteries using formula (peak systolic velocity - end-diastolic velocity) / peak systolic velocity
|
6 months
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Dapa recurrent ascites
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Cirrhose
-
Conatus Pharmaceuticals Inc.AfsluttetLeversygdomme | Levercirrhose | Leverfibrose | NASH Fibrose | Dekompenseret ikke-alkoholisk Steatohepatitis Cirrhosis | Ortotopisk levertransplantationForenede Stater
-
Universidade Federal do Rio de JaneiroIkke rekrutterer endnuPortal hypertension | Idiopatisk ikke-cirrhotisk portalhypertension | Ikke-cirrhotisk portalhypertension | Vaskulær lidelse i leveren | Ikke-cirrhotisk portalfibrose | Regenerativ nodulær hyperplasi | Ufuldstændig septal cirrhosis | Obliterativ Portal Venopati | Hepatoportal sklerose | Idiopatisk Portal HypertensionBrasilien
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... og andre samarbejdspartnereRekrutteringCirrhose | Cirrhose, lever | Cirrhose på grund af hepatitis B | Cirrhose på grund af hepatitis C | Cirrhose tidligt | Cirrhosis Avanceret | Cirrhose Infektiøs | Skrumpelever Alkoholisk | Cirrose, galdevejr | Skrumpelever kryptogenisk | Cirrhose på grund af primær skleroserende kolangitisForenede Stater
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... og andre samarbejdspartnereRekrutteringCirrhose | Cirrhose, lever | Cirrhose på grund af hepatitis B | Cirrhose på grund af hepatitis C | Cirrhose tidligt | Cirrhosis Avanceret | Cirrhose Infektiøs | Skrumpelever Alkoholisk | Cirrose, galdevejr | Skrumpelever kryptogenisk | Cirrhose på grund af primær skleroserende kolangitisForenede Stater
Kliniske forsøg med Dapagliflozin (10Mg Tab) along with standard medical therapy
-
Hospital Israelita Albert EinsteinAfsluttet
-
The University of Hong KongIkke rekrutterer endnuKroniske nyresygdomme | Lupus nefritisHong Kong